BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 27036915)

  • 1. Target Density, Not Affinity or Avidity of Antigen Recognition, Determines Adoptive T Cell Therapy Outcomes in a Mouse Lymphoma Model.
    Segal G; Prato S; Zehn D; Mintern JD; Villadangos JA
    J Immunol; 2016 May; 196(9):3935-42. PubMed ID: 27036915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigen-specific impairment of adoptive T-cell therapy against cancer: players, mechanisms, solutions and a hypothesis.
    Villadangos JA
    Immunol Rev; 2016 Jul; 272(1):169-82. PubMed ID: 27319350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.
    Janicki CN; Jenkinson SR; Williams NA; Morgan DJ
    Cancer Res; 2008 Apr; 68(8):2993-3000. PubMed ID: 18413769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid deletion and inactivation of CTLs upon recognition of a number of target cells over a critical threshold.
    Prato S; Zhan Y; Mintern JD; Villadangos JA
    J Immunol; 2013 Oct; 191(7):3534-44. PubMed ID: 24018271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
    De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
    J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy.
    Chakraborty M; Abrams SI; Camphausen K; Liu K; Scott T; Coleman CN; Hodge JW
    J Immunol; 2003 Jun; 170(12):6338-47. PubMed ID: 12794167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells.
    Sun JB; Eriksson K; Li BL; Lindblad M; Azem J; Holmgren J
    Clin Immunol; 2004 Jul; 112(1):35-44. PubMed ID: 15207780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic limitations in tumor-specific CD8+ memory T cell engraftment.
    Bathe OF; Dalyot-Herman N; Malek TR
    BMC Cancer; 2003 Jul; 3():21. PubMed ID: 12882650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination.
    Chambers B; Grufman P; Fredriksson V; Andersson K; Roseboom M; Laban S; Camps M; Wolpert EZ; Wiertz EJ; Offringa R; Ljunggren HG; van Hall T
    Cancer Res; 2007 Sep; 67(18):8450-5. PubMed ID: 17875682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
    Riquelme E; Carreño LJ; González PA; Kalergis AM
    Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
    Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
    Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies.
    Sandri S; Bobisse S; Moxley K; Lamolinara A; De Sanctis F; Boschi F; Sbarbati A; Fracasso G; Ferrarini G; Hendriks RW; Cavallini C; Scupoli MT; Sartoris S; Iezzi M; Nishimura MI; Bronte V; Ugel S
    Cancer Res; 2016 May; 76(9):2540-51. PubMed ID: 27197263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A combination hybrid-based vaccination/adoptive cellular therapy to prevent tumor growth by involvement of T cells.
    Savai R; Schermuly RT; Pullamsetti SS; Schneider M; Greschus S; Ghofrani HA; Traupe H; Grimminger F; Banat GA
    Cancer Res; 2007 Jun; 67(11):5443-53. PubMed ID: 17545626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
    Guinn BA; DeBenedette MA; Watts TH; Berinstein NL
    J Immunol; 1999 Apr; 162(8):5003-10. PubMed ID: 10202049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression of extensive pulmonary metastases in mice by adoptive transfer of antigen-specific CD8(+) CTL reactive against tumor cells expressing a naturally occurring rejection epitope.
    Ryan MH; Bristol JA; McDuffie E; Abrams SI
    J Immunol; 2001 Oct; 167(8):4286-92. PubMed ID: 11591751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precursor frequency can compensate for lower TCR expression in T cell competition during priming in vivo.
    Rechtsteiner G; Warger T; Hofmann M; Rammensee HG; Schild H; Radsak MP
    Eur J Immunol; 2006 Oct; 36(10):2613-23. PubMed ID: 16955523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
    Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
    Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs.
    Zhang Y; Wakita D; Chamoto K; Narita Y; Matsubara N; Kitamura H; Nishimura T
    Int Immunol; 2007 Feb; 19(2):151-61. PubMed ID: 17189593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leveraging TCR Affinity in Adoptive Immunotherapy against Shared Tumor/Self-Antigens.
    Miller AM; Bahmanof M; Zehn D; Cohen EEW; Schoenberger SP
    Cancer Immunol Res; 2019 Jan; 7(1):40-49. PubMed ID: 30482746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.